Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors.
- 1Department of Medical Oncology, Hospital Universitario de Navarra (HUN), Unidad de Oncología Médica Traslacional, Navarrabiomed-IdiSNA, Pamplona, Spain.
- 2Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- 3Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain.
Abstract
Gastroesophageal adenocarcinoma (GEA) remains a major cause of cancer morbidity and mortality, with substantial geographic variation and marked inter- and intratumoral heterogeneity. The implementation of predictive biomarkers, including human epidermal growth factor 2 (HER2) overexpression/amplification, programmed death ligand 1 (PD-L1) expression, deficient mismatch repair/high microsatellite instability (dMMR/MSI-H), and claudin 18.2 (CLDN18.2), has redefined first-line treatment and enabled biomarker-directed therapeutic selection. Nevertheless, most patients eventually progress, reflecting imperfect biomarker performance, spatial and temporal heterogeneity, coexpression patterns, and complex tumor microenvironment (TME) interactions. Beyond PD-L1, emerging biomarkers such as Epstein-Barr virus (EBV) status, tumor mutational burden (TMB), and transcriptomic immune signatures provide deeper insight into tumor immunogenicity, although their predictive value remains inconsistent. To overcome resistance, novel therapeutic strategies are targeting alternative inhibitory immune checkpoints [cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with Ig and ITIM domain (TIGIT), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3)] and costimulatory pathways (e.g. CD137/TNF receptor superfamily member 9; normally named 4-1BB), as well as emerging targets such as B7-H3 and immunoregulatory axes including C-C motif chemokine receptor 8 (CCR8), Dickkopf-related protein 1 (DKK1), transforming growth factor beta (TGF-β), and prostaglandin E2 receptor 4 (EP4). Concurrently, emerging targetable alterations such as fibroblast growth factor receptor 2b (FGFR2b) and mesenchymal-epithelial transition factor (MET) are reshaping precision treatment, whereas next-generation platforms, including bispecific antibodies, antibody-drug conjugates, and adoptive cellular therapies, are expanding therapeutic opportunities beyond conventional targeted approaches. Notably, these advances have been achieved mainly in the advanced disease setting, whereas approaches for localized GEA remain a critical unmet need. Future progress will require a deeper understanding of the tumor-TME interactions, through integrated, longitudinal, and multidimensional biomarker frameworks that capture genomic, transcriptomic, and immune contexture, alongside adaptive trial designs and equitable access to molecular testing and targeted therapies, to refine precision oncology and improve outcomes in this biologically complex disease.
Related
- Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
- Dissecting shared genetic susceptibility between gastroesophageal reflux disease and psychiatric disorders beyond body mass index
- Phyllodes Tumors of the Breast in 2026: A Contemporary Narrative Review of Diagnosis, Surgical Margins, Prognosis, and Emerging Therapies
- Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
- Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?
BibTeX
@article{alsina2026beyond,
title = {{Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors.}},
author = {M Alsina and E Terán and T Fleitas Kanonnikoff},
journal = {ESMO gastrointestinal oncology},
year = {2026},
month = oct,
doi = {10.1016/j.esmogo.2026.100430},
url = {https://europepmc.org/article/MED/42927317},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors.
AU - M Alsina
AU - E Terán
AU - T Fleitas Kanonnikoff
PY - 2026
DA - 2026/10/17
JO - ESMO gastrointestinal oncology
DO - 10.1016/j.esmogo.2026.100430
UR - https://europepmc.org/article/MED/42927317
AB - Gastroesophageal adenocarcinoma (GEA) remains a major cause of cancer morbidity and mortality, with substantial geographic variation and marked inter- and intratumoral heterogeneity. The implementation of predictive biomarkers, including human epidermal growth factor 2 (HER2) overexpression/amplification, programmed death ligand 1 (PD-L1) expression, deficient mismatch repair/high microsatellite instability (dMMR/MSI-H), and claudin 18.2 (CLDN18.2), has redefined first-line treatment and enabled biomarker-directed therapeutic selection. Nevertheless, most patients eventually progress, reflecting imperfect biomarker performance, spatial and temporal heterogeneity, coexpression patterns, and complex tumor microenvironment (TME) interactions. Beyond PD-L1, emerging biomarkers such as Epstein-Barr virus (EBV) status, tumor mutational burden (TMB), and transcriptomic immune signatures provide deeper insight into tumor immunogenicity, although their predictive value remains inconsistent. To overcome resistance, novel therapeutic strategies are targeting alternative inhibitory immune checkpoints [cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with Ig and ITIM domain (TIGIT), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3)] and costimulatory pathways (e.g. CD137/TNF receptor superfamily member 9; normally named 4-1BB), as well as emerging targets such as B7-H3 and immunoregulatory axes including C-C motif chemokine receptor 8 (CCR8), Dickkopf-related protein 1 (DKK1), transforming growth factor beta (TGF-β), and prostaglandin E2 receptor 4 (EP4). Concurrently, emerging targetable alterations such as fibroblast growth factor receptor 2b (FGFR2b) and mesenchymal-epithelial transition factor (MET) are reshaping precision treatment, whereas next-generation platforms, including bispecific antibodies, antibody-drug conjugates, and adoptive cellular therapies, are expanding therapeutic opportunities beyond conventional targeted approaches. Notably, these advances have been achieved mainly in the advanced disease setting, whereas approaches for localized GEA remain a critical unmet need. Future progress will require a deeper understanding of the tumor-TME interactions, through integrated, longitudinal, and multidimensional biomarker frameworks that capture genomic, transcriptomic, and immune contexture, alongside adaptive trial designs and equitable access to molecular testing and targeted therapies, to refine precision oncology and improve outcomes in this biologically complex disease.
SN - 2949-8198
ER -